Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Not yet recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3CNS 3

Conditions

Neurofibromatosis 1 19Neurofibroma, Plexiform 11Neurofibrosarcoma 3Sarcoma 1Peripheral Nervous System Diseases 1Pain 1Optic Nerve Glioma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Meningioma 1Lymphoma, Non-Hodgkin 1Heredodegenerative Disorders, Nervous System 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 3AZD 6244 3fludarabine phosphate 2Specimen Handling 2Nivolumab 2Etoposide 2thymoglobulin 1pembrolizumab 1lorvotuzumab mertansine 1fludarabine 1X-Rays 1Trabectedin 1Thiotepa 1Tacrolimus 1Surgical Procedures, Operative 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy 1Photons 1Neurofibromin 1 1Mycophenolic Acid 1Mesna 1Melphalan 1Liquid Biopsy 1Ipilimumab 1Imatinib Mesylate 1Ifosfamide 1High-Energy Shock Waves 1Filgrastim 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neurofibrosarcoma × AZD 6244 × CNS × Clear all
NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
21 enrolled 12 charts
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

University of Alabama at Birmingham

Phase 2 Not yet recruiting
41 enrolled
CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT06735820 2025-07-03

MEKMDM2

Children's National Research Institute

Phase 1/2 Not yet recruiting
45 enrolled
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡